What are the indications for adalimumab, how immunosuppressive is it, and does a patient starting it require latent tuberculosis treatment?

Adalimumab: Indications, Immunosuppression, and Latent TB Treatment Requirements

Yes, patients starting adalimumab absolutely require screening for latent tuberculosis and prophylactic treatment if positive, as adalimumab is highly immunosuppressive with one of the highest TB reactivation risks among biologics.

Indications for Adalimumab

Adalimumab (HUMIRA) is FDA-approved for multiple autoimmune inflammatory conditions 1:

• Rheumatologic: Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis
• Dermatologic: Plaque psoriasis, hidradenitis suppurativa
• Gastrointestinal: Crohn's disease, ulcerative colitis (though recent guidelines suggest it is not recommended for moderate-to-severe ulcerative colitis due to trivial benefit compared to other available agents 2)
• Ophthalmologic: Uveitis

Degree of Immunosuppression

Adalimumab is significantly immunosuppressive as a TNF-α antagonist. The evidence demonstrates:

• Highest TB risk among biologics: Adalimumab carries a relative risk of 29.3 for tuberculosis reactivation, the highest among TNF-α inhibitors, compared to infliximab at 18.6 3
• Increased serious infection risk: Patients face elevated risk for opportunistic infections including bacterial, mycobacterial, invasive fungal, viral, and parasitic pathogens 1
• Disseminated disease pattern: When infections occur, they frequently present as disseminated rather than localized disease 1
• Risk amplification: The immunosuppression is compounded when combined with other immunosuppressants like methotrexate, corticosteroids, or other DMARDs 4, 5

Mandatory Latent TB Screening and Treatment

Pre-Treatment Screening Protocol

All patients must undergo comprehensive TB screening before starting adalimumab 4, 6, 4:

1. Chest radiograph (Grade 1C recommendation) 4
2. Tuberculin skin test (TST) to screen for latent TB (Grade 1C) 4, 6
   • Consider ≥5 mm induration positive, even in BCG-vaccinated patients 1
   • Two-step TST may be needed per local guidelines 5, 7
3. Interferon-gamma release assay (IGRA) - preferred over TST where available, especially in BCG-vaccinated populations (Grade 2b) 6, 8
   • IGRAs have higher specificity than TST in BCG-vaccinated patients 3
   • Combined TST/IGRA increases sensitivity and reduces missed cases 9
4. Clinical history: TB exposure, residence/travel to endemic areas, prior TB treatment 5

When Latent TB Treatment is Required

Prophylactic treatment following published guidelines before initiating adalimumab is mandatory (Grade 1B) 4, 6, 4 if:

• Positive TST or IGRA result
• Chest X-ray consistent with prior TB
• History of inadequately treated TB
• High-risk individuals (e.g., Black Africans >15 years, South Asians born outside UK) 5

Prophylaxis Regimens

Standard options 5, 7:

• Isoniazid 300 mg daily for 9 months (preferred)
• Rifampin 600 mg daily for 4 months (alternative)
• Isoniazid 300 mg + Rifampin 600 mg daily for 3 months (combination option)

Critical Timing

Complete at least 1 month of latent TB treatment before starting adalimumab 7. Ideally, complete the full prophylaxis course before initiating therapy, though urgent clinical situations may permit earlier start after minimum 1 month of prophylaxis 5, 7.

Important Caveats and Pitfalls

Screening Limitations

• False negatives occur: TST and IGRA can be falsely negative during immunosuppressive therapy 1
• Patients on concurrent immunosuppressants: Tuberculin testing may be unreliable; use risk stratification instead 5
• 1-3% develop active TB despite appropriate screening and prophylaxis 10, 11, indicating imperfect protection

Ongoing Vigilance Required

• Monitor for TB up to 6 months after discontinuing adalimumab (Grade 1C) 4, 6
• Maintain high clinical suspicion throughout treatment, especially in patients who travel to TB-endemic areas 1
• Extrapulmonary and disseminated TB is more common with adalimumab than typical TB presentations 5, 3, 12
• Consider repeat screening in patients with ongoing TB exposure risk 3, 9

Contraindications

• Do not start adalimumab with active TB infection - exclude active disease before initiating therapy (Grade 1C) 4, 6
• Do not start with any active infection, including localized infections 1

Special Populations

• Patients ≥65 years and those with comorbidities have greater infection risk 1
• BCG-vaccinated populations: Use IGRA preferentially or combined TST/IGRA approach 3, 9
• Endemic mycoses regions: Consider fungal infections in differential diagnosis of systemic illness 1

If TB Develops During Treatment

• Discontinue adalimumab immediately if serious infection develops 1
• Beware of immune reconstitution inflammatory syndrome (IRIS) upon discontinuation 3, 13
• Reintroduction of anti-TNF therapy may be needed to manage IRIS 3

Bottom line: The high TB reactivation risk with adalimumab makes latent TB screening and prophylactic treatment non-negotiable components of safe prescribing practice.